Project Grant K99CA303792
Award Date
7/14/25
Completion Date
6/30/27
Dollars Obligated
$125K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) in the amount of $121,857 aims to systematically investigate how anti-cancer drugs modulate T cells in the tumor microenvironment. The key objectives are to: Conduct in silico screening to identify anti-cancer drugs impacting T cell effector function, activation, stemness, and proliferation (Aim I). Perform single-cell CRISPR knockout screening to determine anti-cancer drug targets...
This $312,892 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research at Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to better understand how ILC3s and their secretion of interleukin-17 (IL-17) can create an immunosuppressive environment that hinders the effectiveness of immune checkpoint inhibitor (ICI) therapy for...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...
This Project Grant award of $127,629, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports a multi-omic research study on the role of human leukocyte antigen (HLA) variations in immune response and efficacy of immune checkpoint inhibitor (ICI) monotherapy for non-small cell lung cancer (NSCLC). The key products and services to be delivered under this 2-year award include: Identifying the mechanisms linking germline and somatic HLA...
This $103,948 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at elucidating the mechanisms driving T-cell dysfunction within the tumor microenvironment. The research plan includes two main components: Predoctoral research (Aim 1) to investigate how local amino acid availability limits effector function in tumor-infiltrating T-cells, including profiling the...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides funding to support the computational research and platform development activities of a laboratory-based research specialist at the Cleveland Clinic Lerner College of Medicine. The key products and services delivered under this $212,567 award, spanning from September 2024 to August 2029, include: Computational analysis of cancer patient-derived next-generation...
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
This $509,448 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) supports research by The Leland Stanford Junior University to investigate antigen-presenting cells in lymph nodes and their role in modulating metastatic tumor progression. The key objectives are to: 1) identify the specific antigen-presenting cell populations responsible for promoting tumor-specific regulatory T cell development, and 2) assess therapeutic strategies to reprogram...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
The National Cancer Institute (NCI) awarded a $149,804 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pittsburgh. The award will fund research to investigate the impact of the LAG3 protein on CD8+ T cell motility and migration in the context of cancer immunotherapy. The project aims to elucidate the mechanism by which LAG3 restricts T cell motility and determine if reduced motility impacts T cell infiltration into the tumor microenvironment. The...